InvestSMART

Neurizon Therapeutics Limited (ASX: NUZ) - Share Price

Current share price for NUZ : $0.075 0.001 (1.32%)+

Neurizon Therapeutics Limited (NUZ) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is engaged in the development of its own drug discovery intellectual property for the treatment of neurological diseases.

NUZ General Information +

ASX Code NUZ
Website http://www.neurizon.com
Industry/Sector Pharmaceuticals
Market Cap ($M) 59
NUZ Share Price $0.075
Day High $0.080
Day Low $0.075
Last Close $0.076
NUZ Share Price Movement $0.00 ( 1.32% )
Prices as at 16:40, 14 Sep 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Neurizon Therapeutics Limited (NUZ) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Neurizon Therapeutics Limited (NUZ) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Neurizon Therapeutics Limited (NUZ) price-sensitive announcements

NUZ - Appendix 4E and 2026 Annual Report
The 2026 Annual Report for Neurizon Therapeutics Limited covers financial statements and a
Neurizon Therapeutics Limited (NUZ)
25 Aug 2026 | 2:58 PM
NUZ - Appendix 4C & Quarterly Update
Neurizon Therapeutics Limited, an Australian biotech company, provided its quarterly activ
Neurizon Therapeutics Limited (NUZ)
31 Jul 2026 | 3:32 PM
NUZ - Neurizon Enters Strategic R&D Financing Facility
Neurizon Therapeutics Limited has entered into a strategic R&D financing facility with Dar
Neurizon Therapeutics Limited (NUZ)
31 Jul 2026 | 3:21 PM
NUZ - HEALEY Enrolment Complete - Topline Accelerated to Q2 CY27
Neurizon Therapeutics Limited announced the completion of enrolment in Regimen I of the HE
Neurizon Therapeutics Limited (NUZ)
17 Jul 2026 | 9:25 AM

Neurizon Therapeutics Limited (NUZ) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Neurizon Therapeutics Limited (NUZ)
ORDINARY FULLY PAID
Health Care $59 Neurizon Announces Partial Redemption of Convertible Notes 10 Sep 2026 9:53AM $0.085 $0.075 fallen by 11.76%
Neurizon Therapeutics Limited (NUZ)
ORDINARY FULLY PAID
Health Care $59 Application for quotation of securities - NUZ 10 Sep 2026 9:18AM $0.085 $0.075 fallen by 11.76%
Neurizon Therapeutics Limited (NUZ)
ORDINARY FULLY PAID
Health Care $59 NIH funds Expanded Access Program for NUZ-001 in ALS 9 Sep 2026 9:55AM $0.062 $0.075 risen by 20.97%
Neurizon Therapeutics Limited (NUZ)
ORDINARY FULLY PAID
Health Care $59 Neurizon Appoints Chief Executive Officer 7 Sep 2026 9:02AM $0.056 $0.075 risen by 33.93%
Neurizon Therapeutics Limited (NUZ)
ORDINARY FULLY PAID
Health Care $59 Application for quotation of securities - NUZ 26 Aug 2026 11:49AM $0.058 $0.075 risen by 29.31%
Neurizon Therapeutics Limited (NUZ)
ORDINARY FULLY PAID
Health Care $59 Appendix 4G and Corporate Governance Statement 25 Aug 2026 3:03PM $0.057 $0.075 risen by 31.58%

NUZ Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$10.72 -$1.80 -47.50% 0.00 0.00 0.00% 0.0%
2025A -$16.59 -$3.40 117.50% 0.00 0.00 0.00% 0.0%
2024A -$5.79 -$1.50 54.00% 0.00 0.00 0.00% 0.0%

NUZ Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
Clarity Pharmaceuticals Ltd (CU6) $825M 0.4454 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Neuren Pharmaceuticals Limited (NEU) $2,567M -0.7857 0.2462 0.9655 87.0219 69.8276 35.5263 0.00% 1.63% 1.93%
Neurizon Therapeutics Limited (NUZ) $60M -0.4746 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

NUZ Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 4.49 0.00
Market 0.34 13.70 1.16 0.80
Sector 0.64 36.60 2.82 4.93

NUZ Directors

Name Position Start Date
Mr Sergio Duchini Non-Executive Chairman, Non-Executive Director 17 May 2024
Dr Ross Murdoch Non-Executive Director 8 May 2026
Dr Kathryn(Katie) MacFarlane Non-Executive Director 17 Jun 2024
Mr Marcus Hughes Non-Executive Director 9 May 2024

Neurizon Therapeutics Limited (NUZ) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
30 Jun 2026 HUGHES, Marcus Buy Direct Shares 46,822 $0.058 $2,715.680
29 Jun 2026 HUGHES, Marcus Buy Direct Shares 3,340 $0.058 $193.720
26 Jun 2026 HUGHES, Marcus Buy Direct Shares 26,778 $0.058 $1,553.120

See all changes in directors' interest & trades for Neurizon Therapeutics Limited (NUZ) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

NUZ Management

Name Position
Daniel O'Connell Chief Financial Officer
Stefan Ross Company Secretary

NUZ Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Neurizon Therapeutics Limited (NUZ). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
21,000,000 (7.49%) Hybrid Holdings Pty Ltd

NUZ Calendar of Events

Date Event
24 August 2027 Report (Annual)
24 August 2027 Report (Prelim)
24 February 2027 Report (Interim)
10 November 2026 AGM

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.